MRG 201

Drug Profile

MRG 201

Alternative Names: miR-29 replacement; MRG-201

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer miRagen Therapeutics; Yale University
  • Class Antifibrotics; MicroRNAs; Skin disorder therapies
  • Mechanism of Action Collagen inhibitors; RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Fibrosis
  • Preclinical Pulmonary fibrosis

Most Recent Events

  • 11 Sep 2017 Pharmacodynamics data from a preclinical trial in Pulmonnary fibrosis presented at the European Respiratory Society International Congress (ERS-2017)
  • 01 Sep 2017 Preclinical trials in Pulmonary fibrosis in USA (Inhalation) before September 2017
  • 11 Aug 2017 miRagen Therapeutics plans a phase IIa trial for Fibrosis in patients with a predisposition for keloid formation in the second quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top